Developer docs
API playgroundTry for free, no card

Search company profiles

Minicircle

Full company profile

uuid003vmu6

Namestring
Minicircle
Legal namestring
Minicircle Inc
Websiteurl
minicircle.org
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Minicircle is a private US-based gene therapy company developing a non-viral plasmid platform targeting human longevity, anti-aging, and performance enhancement. The company currently offers Follistatin, a plasmid gene therapy administered via subcutaneous injection that is reported to support lean muscle growth, reduce body fat, and lower epigenetic age, with effects described as non-heritable and lasting approximately one year. A second product, Klotho, is in development with anticipated release at overseas clinics in 2026. All therapies are investigational, have not been reviewed by the FDA, and are administered by licensed clinicians at independent international partner clinics operating under regulatory frameworks outside the United States.

The business model is consumer-direct, quote-based pricing with patients joining a waitlist via the company website; revenue flows from per-treatment administration rather than subscription or licensing. Distribution is exclusively through partner clinics in jurisdictions with permissive regulatory regimes — specifically Honduras (including the Próspera/Vitalia zone on Roatán), the Bahamas, and Panama — a structure that allows the company to commercialize therapies that have not completed US clinical trials. Go-to-market is concentrated in the biohacking and longevity enthusiast segment, with marketing anchored on testimonials from Bryan Johnson, Ben Greenfield, Kenneth Scott, and a feature in the Netflix documentary "Don't Die: The Man Who Wants to Live Forever."

The company was founded in 2019, operates with 11-50 employees, and is led by founder and CEO Mac Davis. Total disclosed funding is modest, with a 2021 round from Quiet Capital and Sprint VC and a 2024 round of $458,511 from Gaingels. The entity is incorporated in the United States as Minicircle Inc, headquartered in Austin, Texas (with conflicting firmographic data listing Los Angeles). The company has administered 100+ therapies cumulatively and positions itself as a gene therapy platform rather than a medical provider.

Short descriptiontext

Minicircle is a US-based private gene therapy company that administers non-viral plasmid therapies (Follistatin, with Klotho launching in 2026) through international clinic partners in Honduras, the Bahamas, and Panama, serving affluent longevity enthusiasts and biohackers seeking FDA-cleared alternatives.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
plasmid gene therapy, longevity therapeutics, anti-aging treatments, non-viral gene delivery, wellness gene therapy
Industry2 codes
PRIMARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Administration
TypeOne Time License
Description

Minicircle generates revenue by providing plasmid gene therapies (Follistatin currently, Klotho coming 2026) through independent international partner clinics. The therapies are administered via subcutaneous injection at select clinics in Central America.

minicircle.io
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1Gene therapy treatment pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Not publicly disclosed. Patients interested in receiving gene therapies must complete contact form to join waitlist and receive pricing information.

minicircle.io
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Minicircle is a gene therapy platform that develops and provides non-viral plasmid-based gene therapies for longevity, performance, and wellness. Its current product, Follistatin, is a plasmid gene therapy administered via subcutaneous injection to support lean muscle growth, reduce body fat, and lower epigenetic age. Treatments are delivered through licensed clinicians at independent international partner clinics in Central America (Honduras, Bahamas, Panama) outside US FDA jurisdiction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Clinical trial participants experienced average 2-pound increase in fat-free mass
+3 more records
Product overview1 text field

Minicircle is a gene therapy platform offering plasmid-based gene therapies for longevity, performance, and wellness. The company provides two primary therapeutic products: Follistatin (currently available) and Klotho (launching 2026). Follistatin is a non-viral plasmid gene therapy administered via subcutaneous injection that supports lean muscle growth, reduces body fat, and lowers epigenetic age. Klotho is an anti-aging gene therapy targeting the klotho protein. All therapies are investigational, have not been reviewed by the FDA, and are administered by licensed clinicians at independent international partner clinics operating outside the United States.

Product and service1 record
1Follistatin
CategoryGene Therapy
Description

Plasmid gene therapy designed to increase follistatin protein production, supporting lean muscle growth, fat reduction, and long-term vitality. Administered via subcutaneous injection, with non-heritable effects lasting approximately 1 year. Clinical trial participants experienced an average 2-pound increase in fat-free mass, 0.87% body fat reduction, and a 12-year reduction in epigenetic age in aged participants. For individual consumers seeking longevity and performance optimization.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Independent International Clinic Partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Minicircle partners with licensed clinicians at independent international health clinics operating under regulatory frameworks outside the United States. These clinic partners administer Minicircle's gene therapies (Follistatin, Klotho) to patients. The company explicitly states 'all therapies are administered by licensed clinicians at independent international partner clinics operating under regulatory frameworks outside the United States.'

minicircle.io
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Minicircle completed a follistatin gene-therapy study in the Próspera/Vitalia zone on Roatán, Honduras. This private city operates as an autonomous zone under special economic zone laws and has attracted biotech startups and medical tourists seeking gene therapies that face regulatory restrictions elsewhere. Despite legal challenges to ZEDE laws, Minicircle has conducted clinical research in this jurisdiction.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-driven drug discovery company with a longevity pipeline (including Klotho-related programs). Competes for the same investor and patient attention in longevity biotech and represents a potential strategic acquirer of Minicircle's plasmid platform.

2AgeX Therapeutics
TypeEmerging player
Description

Biotech focused on cellular rejuvenation and induced tissue regeneration (iTR) for aging. Pursues longevity therapeutics through a different modality (pluripotent stem cell-derived treatments) but the same anti-aging target market and scientific framework.

TypeEmerging player
Description

Regenerative medicine biotech developing recombinant GDF11 for age-related diseases. Targets the same longevity/healthy-lifespan customer thesis as Minicircle but pursues FDA-regulated development paths with larger funding.

TypeDirect peer
Description

Libella offered gene therapies (including telomerase) for longevity through clinical trials conducted in Colombia to avoid US regulation — a near-identical strategy to Minicircle's Central American clinic model for accessing experimental anti-aging therapies.

TypeEmerging player
Description

George Church spin-out using gene therapy (including follistatin) to treat age-related diseases in companion animals and humans. Direct methodological overlap with Minicircle's follistatin therapy and similar gene-therapy-for-aging thesis.

TypeEmerging player
Description

Clinical-stage biotech developing senolytic therapies for age-related diseases. Mentioned alongside Minicircle in press coverage of longevity/transhumanist technologies. Pursues the same aging patient market through formal FDA pathways.

TypeDirect peer
Description

BioViva is a direct peer offering experimental gene therapies for aging and longevity, including telomere and follistatin therapies, administered offshore to bypass FDA. Mirrors Minicircle's regulatory-arbitrage, longevity-tourism business model and target customer base.

8CohBar
TypeEmerging player
Description

Clinical-stage biotech developing mitochondria-derived peptides (MBTs) for age-related diseases including NASH, obesity, and cancer. Competes for the same anti-aging biology platform investment thesis as Minicircle.

9Maximum Life Foundation
TypeOthers
Description

Non-profit focused on advancing regenerative and gene therapies for human longevity. Operates as ecosystem participant/advisor in the same niche as Minicircle and has publicly backed similar telomere/gene therapy clinical research.

TypeEmerging player
Description

Biotech developing FDA-conditional longevity drugs for dogs. Operates in the broader animal/human longevity therapeutics category and competes for the same longevity-investor capital and brand narrative as Minicircle.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Minicircle

Gene Therapyminicircle.org

Minicircle is a US-based private gene therapy company that administers non-viral plasmid therapies (Follistatin, with Klotho launching in 2026) through international clinic partners in Honduras, the Bahamas, and Panama, serving affluent longevity enthusiasts and biohackers seeking FDA-cleared alternatives.

What Minicircle does

Minicircle is a private US-based gene therapy company developing a non-viral plasmid platform targeting human longevity, anti-aging, and performance enhancement. The company currently offers Follistatin, a plasmid gene therapy administered via subcutaneous injection that is reported to support lean muscle growth, reduce body fat, and lower epigenetic age, with effects described as non-heritable and lasting approximately one year. A second product, Klotho, is in development with anticipated release at overseas clinics in 2026. All therapies are investigational, have not been reviewed by the FDA, and are administered by licensed clinicians at independent international partner clinics operating under regulatory frameworks outside the United States.

The business model is consumer-direct, quote-based pricing with patients joining a waitlist via the company website; revenue flows from per-treatment administration rather than subscription or licensing. Distribution is exclusively through partner clinics in jurisdictions with permissive regulatory regimes — specifically Honduras (including the Próspera/Vitalia zone on Roatán), the Bahamas, and Panama — a structure that allows the company to commercialize therapies that have not completed US clinical trials. Go-to-market is concentrated in the biohacking and longevity enthusiast segment, with marketing anchored on testimonials from Bryan Johnson, Ben Greenfield, Kenneth Scott, and a feature in the Netflix documentary "Don't Die: The Man Who Wants to Live Forever."

The company was founded in 2019, operates with 11-50 employees, and is led by founder and CEO Mac Davis. Total disclosed funding is modest, with a 2021 round from Quiet Capital and Sprint VC and a 2024 round of $458,511 from Gaingels. The entity is incorporated in the United States as Minicircle Inc, headquartered in Austin, Texas (with conflicting firmographic data listing Los Angeles). The company has administered 100+ therapies cumulatively and positions itself as a gene therapy platform rather than a medical provider.

Minicircle firmographics

Firmographics
Name
Minicircle
Legal name
Minicircle Inc
Website
https://minicircle.org
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Minicircle is a US-based private gene therapy company that administers non-viral plasmid therapies (Follistatin, with Klotho launching in 2026) through international clinic partners in Honduras, the Bahamas, and Panama, serving affluent longevity enthusiasts and biohackers seeking FDA-cleared alternatives.
Ownership category
akta.pro rank

Minicircle industry classification

Industry
Product category
Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Plasmid gene therapy
  • Longevity therapeutics
  • Anti-aging treatments
  • Non-viral gene delivery
  • Wellness gene therapy

Where Minicircle is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Minicircle business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Gene Therapy Administration: Minicircle generates revenue by providing plasmid gene therapies (Follistatin currently, Klotho coming 2026) through independent international partner clinics. The therapies are administered via subcutaneous injection at select clinics in Central America.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goGene therapy treatment pricing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Minicircle product offering

Product offering

Core offering

Minicircle is a gene therapy platform that develops and provides non-viral plasmid-based gene therapies for longevity, performance, and wellness. Its current product, Follistatin, is a plasmid gene therapy administered via subcutaneous injection to support lean muscle growth, reduce body fat, and lower epigenetic age. Treatments are delivered through licensed clinicians at independent international partner clinics in Central America (Honduras, Bahamas, Panama) outside US FDA jurisdiction.

Product overview

Minicircle is a gene therapy platform offering plasmid-based gene therapies for longevity, performance, and wellness. The company provides two primary therapeutic products: Follistatin (currently available) and Klotho (launching 2026). Follistatin is a non-viral plasmid gene therapy administered via subcutaneous injection that supports lean muscle growth, reduces body fat, and lowers epigenetic age. Klotho is an anti-aging gene therapy targeting the klotho protein. All therapies are investigational, have not been reviewed by the FDA, and are administered by licensed clinicians at independent international partner clinics operating outside the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • Follistatin Plasmid gene therapy designed to increase follistatin protein production, supporting lean muscle growth, fat reduction, and long-term vitality. Administered via subcutaneous injection, with non-heritable effects lasting approximately 1 year. Clinical trial participants experienced an average 2-pound increase in fat-free mass, 0.87% body fat reduction, and a 12-year reduction in epigenetic age in aged participants. For individual consumers seeking longevity and performance optimization.

Quantifiable outcome

  • Clinical trial participants experienced average 2-pound increase in fat-free mass
  • +3 more outcomes

Companies that use Minicircle

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Minicircle technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Minicircle partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Independent International Clinic PartnerscoreChannel Partner/ Reseller/ DistributorMinicircle partners with licensed clinicians at independent international health clinics operating under regulatory frameworks outside the United States. These clinic partners administer Minicircle's gene therapies (Follistatin, Klotho) to patients. The company explicitly states 'all therapies are administered by licensed clinicians at independent international partner clinics operating under regulatory frameworks outside the United States.'
  • Próspera/Vitalia (Honduras)coreStrategic or Co-development PartnerMinicircle completed a follistatin gene-therapy study in the Próspera/Vitalia zone on Roatán, Honduras. This private city operates as an autonomous zone under special economic zone laws and has attracted biotech startups and medical tourists seeking gene therapies that face regulatory restrictions elsewhere. Despite legal challenges to ZEDE laws, Minicircle has conducted clinical research in this jurisdiction.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Minicircle competitors and assessment

Company assessment

Emerging players

  • Insilico Medicine: AI-driven drug discovery company with a longevity pipeline (including Klotho-related programs). Competes for the same investor and patient attention in longevity biotech and represents a potential strategic acquirer of Minicircle's plasmid platform.
  • AgeX Therapeutics: Biotech focused on cellular rejuvenation and induced tissue regeneration (iTR) for aging. Pursues longevity therapeutics through a different modality (pluripotent stem cell-derived treatments) but the same anti-aging target market and scientific framework.
  • Elevian: Regenerative medicine biotech developing recombinant GDF11 for age-related diseases. Targets the same longevity/healthy-lifespan customer thesis as Minicircle but pursues FDA-regulated development paths with larger funding.
  • Rejuvenate Bio: George Church spin-out using gene therapy (including follistatin) to treat age-related diseases in companion animals and humans. Direct methodological overlap with Minicircle's follistatin therapy and similar gene-therapy-for-aging thesis.
  • Unity Biotechnology: Clinical-stage biotech developing senolytic therapies for age-related diseases. Mentioned alongside Minicircle in press coverage of longevity/transhumanist technologies. Pursues the same aging patient market through formal FDA pathways.
  • CohBar: Clinical-stage biotech developing mitochondria-derived peptides (MBTs) for age-related diseases including NASH, obesity, and cancer. Competes for the same anti-aging biology platform investment thesis as Minicircle.
  • Loyal for Dogs: Biotech developing FDA-conditional longevity drugs for dogs. Operates in the broader animal/human longevity therapeutics category and competes for the same longevity-investor capital and brand narrative as Minicircle.

Direct peers

  • Libella Gene Therapeutics: Libella offered gene therapies (including telomerase) for longevity through clinical trials conducted in Colombia to avoid US regulation — a near-identical strategy to Minicircle's Central American clinic model for accessing experimental anti-aging therapies.
  • BioViva: BioViva is a direct peer offering experimental gene therapies for aging and longevity, including telomere and follistatin therapies, administered offshore to bypass FDA. Mirrors Minicircle's regulatory-arbitrage, longevity-tourism business model and target customer base.

Others

  • Maximum Life Foundation: Non-profit focused on advancing regenerative and gene therapies for human longevity. Operates as ecosystem participant/advisor in the same niche as Minicircle and has publicly backed similar telomere/gene therapy clinical research.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Minicircle social profiles

Digital presence

Minicircle financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Minicircle leadership team

Management profile

Number of profiles

Profiles1 record

Minicircle funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Minicircle M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minicircle

What does Minicircle do?

Minicircle is a gene therapy platform that develops and provides non-viral plasmid-based gene therapies for longevity, performance, and wellness. Its current product, Follistatin, is a plasmid gene therapy administered via subcutaneous injection to support lean muscle growth, reduce body fat, and lower epigenetic age. Treatments are delivered through licensed clinicians at independent international partner clinics in Central America (Honduras, Bahamas, Panama) outside US FDA jurisdiction.

Is Minicircle a public or private company?

Minicircle is a private company. It is classified as venture growth investor backed and is currently operating.

When was Minicircle founded?

Minicircle was founded in 2019. It employs 1 to 10 people.

Where is Minicircle based?

Minicircle is headquartered in Los Angeles, United States, in the North America region.

How does Minicircle make money?

One revenue line is on record: gene Therapy Administration.

Who are Minicircle's main competitors?

Emerging players on record are Insilico Medicine, AgeX Therapeutics, Elevian, Rejuvenate Bio, Unity Biotechnology, CohBar and Loyal for Dogs. Direct peers are Libella Gene Therapeutics and BioViva. Maximum Life Foundation is listed as an others.

Does Minicircle have an API?

No public API is recorded for Minicircle.

What industry is Minicircle in?

Minicircle's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyMinicircle named XPRIZE Healthspan finalistMinicircle, an Austin-based gene therapy developer, was named one of 10 finalists in the $101 million XPRIZE Healthspan competition. The company will receive a $1 million finalist cash prize to support a placebo-controlled interventional human clinical trial. Grand prize winners are to be announced in 2030.FinancialContent Business PageMinicircle Named One of 10 Finalists in the $101M XPRIZE Healthspan CompetitionMinicircle was named one of the top 10 finalists in the $101 million XPRIZE Healthspan competition, a seven-year challenge to restore muscle, cognitive, and immune function in adults aged 50–80. The company will receive a $1 million cash prize to support a large placebo-controlled clinical trial, with winners announced in 2030.Business Wire BlogMinicircle Named One of 10 Finalists in the $101M XPRIZE Healthspan CompetitionMinicircle was named one of the top 10 finalists in the $101M XPRIZE Healthspan competition, which seeks rejuvenation therapies for adults aged 50-80. The company will receive a $1 million prize to support a placebo-controlled interventional human clinical trial. Grand prize winners will be announced in 2030.New ScientistUnapproved gene therapy for boosting longevity is set to go on saleMinicircle, a biotech company based in Austin, Texas, has developed a gene therapy designed to increase production of the anti-aging protein klotho and plans to sell it at overseas clinics in Honduras, the Bahamas, and Panama. The treatment lacks FDA approval and has not undergone rigorous clinical trials, with the company using international locations to circumvent US regulatory requirements. The company has opened a waitlist and expects to make the treatment available within six months.New York PostInside the alarming cyborg future 'transhumanists' Elon Musk, Peter Thiel and Sam Altman are preparing forMajor tech executives including Elon Musk, Peter Thiel, and Sam Altman are investing in transhumanist technologies aimed at merging human consciousness with machines or achieving digital immortality, with investments spanning companies like Neuralink, OpenAI's Merge Labs, Minicircle, and Unity Biotechnology. The article presents a critical analysis of this ideology, citing MIT physicist Max Tegmark and tech reporter Taylor Lorenz who argue that transhumanist beliefs are driving reckless AI innovation that prioritizes the vision of tech founders over human wellbeing. Critics warn that the general public finds this vision "horrifying" and question whether humanity would retain autonomy if it "merged" with more intelligent machines.Pharmaceutical TechnologyIn a Honduran city, biotechs create gene therapy cocktails to fight agingBiotech companies Minicircle and Unlimited Bio are operating in Próspera, a charter city on Roatán island in Honduras, to develop gene therapies targeting ageing, attracted by the jurisdiction's permissive regulatory environment. Unlimited Bio plans to begin a Phase I/II trial in January 2026 testing a combined VEGF and follistatin gene therapy regimen in healthy participants over 45, with results expected by April 2026. Industry experts question both the scientific plausibility of combinatorial gene therapies for ageing and whether data gathered in Próspera would be acceptable to regulatory agencies like the FDA or EMA for broader approvals.Business InsiderThe controversial tech millionaire obsessed with anti-aging is undergoing $25K gene therapy not approved by the FDABryan Johnson received his first dose of follistatin gene therapy from Minicircle, costing $25,000 per dose, on a Caribbean island. The FDA has not approved the treatment, and the company has not published trial data. Johnson spends about $2 million annually on his anti-aging program.BloombergOne Man’s Longevity Obsession Now Includes Fountain-of-Youth InjectionsMedical tourists visited Roatán to receive Minicircle Inc.'s gene therapy, delivered via injection, which boosts follistatin production. The company claims it can reduce inflammation, increase muscle and bone density, and extend exercise endurance. The therapy is described as a potential breakthrough for extreme longevity.MIT Technology ReviewThis biohacking company is using a crypto city to test controversial gene therapiesMinicircle is conducting gene therapy trials in Próspera, Honduras, recruiting participants via NFTs and promising crypto payments. The company, backed by investors including Peter Thiel and Sam Altman, aims to democratize access to gene therapies, but experts question its methods and oversight. The trials face uncertainty as Próspera's legal status with Honduras remains unresolved.